Template:COVID-19 vaccine candidates
Jump to navigation
Jump to search
COVID‑19 vaccine candidates in Phase I–II trials (Most advanced clinical research highlighted in green.) |
|||||||
---|---|---|---|---|---|---|---|
Vaccine candidate
(Developer/Sponsor) |
Technology | Phase of trial
(Participants) |
Adverse effects | Immune response | Location | Duration | References/Notes |
Ad5-nCoV
(CanSino Biologics, Institute of Biotechnology of the Academy of Military Medical Sciences) |
Recombinant adenovirus type 5 vector | Phase II interventional trial for dosing and side effects (500) | China | March 2020 to December 2020 | Clinical and manufacturing partnership with the National Research Council of Canada and Canadian Center for Vaccinology, Halifax, Nova Scotia[1][2][3] | ||
Phase I (108) | Moderate over seven days; fever, pain, fatigue[4] | Moderate antibody and T-cell responses[4] | [4][5] | ||||
ChAdOx1 nCoV-19 | Adenovirus vector | Phase I–II, randomized, placebo-controlled, multiple sites (1000) | United Kingdom | April 2020 to May 2021 | [6][7] | ||
BNT162 (a1, b1, b2, c2)
(BioNTech, Fosun Pharma, Pfizer) |
RNA | Phase I–II of four vaccines, randomized, placebo-controlled, dose-finding, vaccine candidate-selection (7600) | Germany United States |
April 2020 to May 2021 | [8][9][10] | ||
unnamed | Inactivated SARS-CoV-2 virus | Phase I–II randomized, double-blinded, single-center, placebo-controlled in Xuzhou (744); Phase I–II in Renqiu (422) | China | •April 2020 to December 2020 in Xuzhou •May to July 2020 in Renqiu |
[11][12] | ||
INO-4800
(Inovio Pharmaceuticals, CEPI, Korea National Institute of Health, International Vaccine Institute) |
DNA plasmid delivered by electroporation | Phase I–II (40) | United States South Korea |
April 2020 to November 2020 | South Korean Phase I–II in parallel with Phase I in the U.S.[13][14] | ||
mRNA-1273
(Moderna, US National Institute of Allergy and Infectious Diseases) |
Lipid nanoparticle dispersion containing messenger RNA | Phase I (45) | United States | March 2020 to Spring-Summer 2021 | [15][16][17] | ||
COVID-19/aAPC
(Shenzhen Geno-Immune Medical Institute) |
Lentiviral vector, pathogen-specific artificial antigen presenting dendritic cells | Phase I (100) | China | March 2020 to 2023 | [15][18] | ||
LV-SMENP-DC
(Shenzhen Geno-Immune Medical Institute) |
Lentiviral minigene vaccine, dendritic cells modified with lentiviral vector | Phase I (100) | China | March 2020 to 2023 | [15][19] | ||
bacTRL-Spike
(Symvivo Corporation, University of British Columbia, Dalhousie University) |
DNA, bacterial medium (oral) | Phase I (84) | Canada | April 2020 to December 2021 | [20] | ||
unnamed
(Beijing Institute of Biological Products, Wuhan Institute of Biological Products) |
Inactivated COVID-19 virus (vero cells) | Phase I (288) | China | April 2020 to November 2021 | Has Phase II design registered for > 1000 participants, including children, not yet recruiting[21][22] | ||
NVX-CoV2373
(Novavax) |
SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant | Phase I (131) | Australia | May 2020 to July 2021 | [23] |
- ↑ Clinical trial number NCT04341389 for "A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)" at ClinicalTrials.gov
- ↑ "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". National Research Council, Government of Canada. 2020-05-12. Retrieved 2020-05-22.
- ↑ Ryan, Haley (2020-05-16). "Canada's first COVID-19 vaccine trials approved for Halifax university". CBC News. Retrieved 2020-05-22.
- ↑ 4.0 4.1 4.2 Zhu, Feng-Cai; Li, Yu-Hua; Guan, Xu-Hua; Hou, Li-Hua; Wang, Wen-Juan; Li, Jing-Xin; Wu, Shi-Po; Wang, Bu-Sen; Wang, Zhao; Wang, Lei; Jia, Si-Yue (2020-05-22). "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial". The Lancet. doi:10.1016/S0140-6736(20)31208-3. ISSN 0140-6736.
- ↑ Clinical trial number NCT04313127 for "A Phase I Clinical Trial in 18-60 Adults" at ClinicalTrials.gov
- ↑ "A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers". Health Research Authority, UK National Health Service. Retrieved 2020-05-10.
- ↑ Clinical trial number NCT04324606 for "A Study of a Candidate COVID-19 Vaccine (COV001)" at ClinicalTrials.gov
- ↑ "EudraCT Number 2020-001038-36". EU Clinical Trials Register. European Union. Retrieved 22 April 2020.
- ↑ "Mainzer Unternehmen Biontech testet Corona-Impfstoff". swr.online (in German). SWR. 22 April 2020. Retrieved 22 April 2020.
- ↑ Clinical trial number NCT04368728 for "Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04352608 for "Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19)" at ClinicalTrials.gov
- ↑ "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. US National Library of Medicine, National Institutes of Health. Retrieved 13 May 2020.
- ↑ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 2020-04-16. Retrieved 2020-04-23.
- ↑ Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov
- ↑ 15.0 15.1 15.2 Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591. Unknown parameter
|name-list-style=
ignored (help) - ↑ "NIH clinical trial of investigational vaccine for COVID-19 begins". US National Institutes of Health. 16 March 2020. Retrieved 17 March 2020.
- ↑ Clinical trial number NCT04283461 for "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04299724 for "Safety and Immunity of Covid-19 aAPC Vaccine" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04276896 for "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04334980 for "Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19" at ClinicalTrials.gov
- ↑ "A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine (vero cells)". Chinese Clinical Trial Registry. 2020-04-11. Retrieved 2020-04-25.
- ↑ "Draft landscape of COVID-19 candidate vaccines – 23 April 2020" (PDF). World Health Organization. 2020-04-23. Retrieved 2020-04-25.
- ↑ Clinical trial number NCT04368988 for "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant" at ClinicalTrials.gov